By the way, have you seen this? The first-ever US guidelines for treating vitiligo in pediatric, adolescent, and young adult patients were published last week, proudly sponsored by the VRF (Vitiligo Research Foundation).
The statement provides specific guidance on dosages, treatment durations and considerations for different age groups. For instance, it backs the twice-daily application of topical calcineurin inhibitors and circumspect use of topical corticosteroids to mitigate the risk of skin atrophy.
It also supports the off-label application of 1.5% ruxolitinib cream as a first-line treatment for children under 12 with nonsegmental vitiligo.
